Protein kinase C mediates induced secretion of vascular endothelial growth factor by human glioma cells

Biochemical and Biophysical Research Communications

Volumn 309, Issue 4, 2003, Pages 952-960

  Tsai, Jui Chang ^a,b   Teng, Lee Jene ^b   Chen, Chin Tin ^b   Hong, Tse Ming ^b   Goldman, Corey K ^c   Gillespie, G Yancey ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c University of Alabama at Birmingham   (United States)

Author keywords

Epidermal growth factor; Fibroblast growth factor; Isozymes; Malignant glioma; Platelet derived growth factor; Protein kinase C; Protein tyrosine kinase; Vascular endothelial growth factor; Vascular permeability factor

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; AG 18; AG 213; CALCIMYCIN; CALCIUM IONOPHORE; GENISTEIN; N (2 GUANIDINOETHYL) 5 ISOQUINOLINESULFONAMIDE; N (2 METHYLAMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; PHORBOL 12 ACETATE 13 MYRISTATE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN;

ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; GLIOMA CELL; HORMONE RELEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0141453284     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.08.106     Document Type: Article

References (35)

1. Plate K.H., Breier G., Weich H.A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 359:1992;845-848.
2. Ferrara N., Houck K., Jakeman L., Leung D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev. 13:1992;18-32.
3. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D.T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246:1989;1309-1312.
4. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
5. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13:1999;9-22.
6. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18:1997;4-25.
7. Tsai J.C., Goldman C.K., Gillespie G.Y. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J. Neurosurg. 82:1995;864-873.
8. Goldman C.K., Kim J., Wong W.L., King V., Brock T., Gillespie G.Y. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell. 4:1993;121-133.
9. Machein M.R., Plate K.H. VEGF in brain tumors. J. Neurooncol. 50:2000;109-120.
10. Swannie H.C., Kaye S.B. Protein kinase C inhibitors. Curr. Oncol. Rep. 4:2002;37-46.
11. Neri L.M., Borgatti P., Capitani S., Martelli A.M. Protein kinase C isoforms and lipid second messengers: a critical nuclear partnership? Histol. Histopathol. 17:2002;1311-1316.
12. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258:1992;607-614.
13. Bradshaw D., Hill C.H., Nixon J.S., Wilkinson S.E. Therapeutic potential of protein kinase C inhibitors. Agents Actions. 38:1993;135-147.
14. Hofmann J. Modulation of protein kinase C in antitumor treatment. Rev. Physiol. Biochem. Pharmacol. 142:2001;1-96.
15. da Rocha A.B., Mans D.R., Regner A., Schwartsmann G. Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist. 7:2002;17-33.
16. Levitzki A. Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J. 6:1992;3275-3282.
17. Bigner D.D., Bigner S.H., Ponten J., Westermark B., Mahaley M.S., Ruoslahti E., Herschman H., Eng L.F., Wikstrand C.J. Heterogeneity of Genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J. Neuropathol. Exp. Neurol. 40:1981;201-229.
18. Kim K.J., Li B., Houck K., Winer J., Ferrara N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 7:1992;53-64.
19. Dvir A., Milner Y., Chomsky O., Gilon C., Gazit A., Levitzki A. The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers. J. Cell Biol. 113:1991;857-865.
20. Rendu F., Eldor A., Grelac F., Bachelot C., Gazit A., Gilon C., Levy-Toledano S., Levitzki A. Inhibition of platelet activation by tyrosine kinase inhibitors. Biochem. Pharmacol. 44:1992;881-888.
21. Spangler R., Joseph C., Qureshi S.A., Berg K.L., Foster D.A. Evidence that v-src and v-fps gene products use a protein kinase C-mediated pathway to induce expression of a transformation-related gene. Proc. Natl. Acad. Sci. USA. 86:1989;7017-7021.
22. Ido M., Nagao Y., Higashigawa M., Shibata T., Taniguchi K., Hamazaki M., Sakurai M. Differential growth inhibition of isoquinolinesulfonamides H-8 and H-7 towards multidrug-resistant P388 murine leukaemia cells. Br. J. Cancer. 64:1991;1103-1107.
23. Junoy B., Maccario H., Mas J.L., Enjalbert A., Drouva S.V. Proteasome implication in phorbol ester- and GnRH-induced selective down-regulation of PKC (alpha, epsilon, zeta) in alpha T(3)-1 and L beta T(2) gonadotrope cell lines. Endocrinology. 143:2002;1386-1403.
24. Lin W.W., Chen B.C. Distinct PKC isoforms mediate the activation of cPLA2 and adenylyl cyclase by phorbol ester in RAW264.7 macrophages. Br. J. Pharmacol. 125:1998;1601-1609.
25. Johnson D.E., Williams L.T. Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res. 60:1993;1-41.
26. Sibley D.R., Benovic J.L., Caron M.G., Lefkowitz R.J. Regulation of transmembrane signaling by receptor phosphorylation. Cell. 48:1987;913-922.
27. Cantley L.C., Auger K.R., Carpenter C., Duckworth B., Graziani A., Kapeller R., Soltoff S. Oncogenes and signal transduction. Cell. 64:1991;281-302.
28. Whitman M., Cantley L. Phosphoinositide metabolism and the control of cell proliferation. Biochim. Biophys. Acta. 948:1989;327-344.
29. Levitzki A., Gilon C. Tyrphostins as molecular tools and potential antiproliferative drugs. Trends Pharmacol. Sci. 12:1991;171-174.
30. Dumas J. Growth factor receptor kinase inhibitors: recent progress and clinical impact. Curr. Opin. Drug Discov. Devel. 4:2001;378-389.
31. Ruegg U.T., Burgess G.M. Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol. Sci. 10:1989;218-220.
32. Hidaka H., Inagaki M., Kawamoto S., Sasaki Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry (Mosc). 23:1984;5036-5041.
33. Nakadate T., Jeng A.Y., Blumberg P.M. Comparison of protein kinase C functional assays to clarify mechanisms of inhibitor action. Biochem. Pharmacol. 37:1988;1541-1545.
34. Herbert J.M., Augereau J.M., Gleye J., Maffrand J.P. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem. Biophys. Res. Commun. 172:1990;993-999.
35. Strulovici B., Daniel-Issakani S., Baxter G., Knopf J., Sultzman L., Cherwinski H., Nestor J. Jr., Webb D.R., Ransom J. Distinct mechanisms of regulation of protein kinase C epsilon by hormones and phorbol diesters. J. Biol. Chem. 266:1991;168-173.